Recent Updates
Recently added Catalysts

BMS-986454

Phase 1

Rheumatoid Arthritis | Small molecule | Immunology |Bristol-Myers Squibb Company|Last Updated: Jun 8, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment46
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07171983A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid ArthritisPHASE1 RECRUITING 46 — — Feb 27, 2026Aug 25, 2027Jun 8, 20269 India
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of participants with adverse events (AEs)
Up to 6 months
Number of participants with serious adverse events (SAEs)
Up to 6 months
Number of participants with physical examination findings
Up to 6 months
Number of participants with vital sign measurement findings
Up to 6 months
Number of participants with 12-lead electrocardiogram (ECG) findings
Up to 6 months
Number of participants with clinical laboratory test findings
Up to 6 months
Secondary Endpoints
Maximum observed concentration (Cmax)
Up to 6 months
Concentration at the end of a dosing interval (Ctau)
Up to 6 months
Trough observed plasma concentration (Ctrough)
Up to 6 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part A: Administration of BMS-986454EXPERIMENTAL -
Part A: PlaceboPLACEBO_COMPARATOR -
Part B: Administration of BMS-986454EXPERIMENTAL -
Part B: PlaceboPLACEBO_COMPARATOR -
Interventions
NameTypeDescription
BMS-986454DRUGSpecified dose on specified days
PlaceboOTHERSpecified dose on specified days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: * Participants with Rheumatoid Arthritis must have onset after age 18. * Participants who meet 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA. * Participants must have evidence of swelling in at least 1 joint o...

Countries:India
Unlock Eligibility Criteria
Competitive Landscape -Rheumatoid Arthritis 97 trials
CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV6PHASE3Upadacitinib, Adalimumab, Tocilizumab, Lutikizumab, Ravagalimab
Eli Lilly and CompanyLLY5PHASE3Baricitinib, Tocilizumab, LY3541860, LY4213663, LY4298445
Bristol-Myers Squibb CompanyBMY6PHASE3Abatacept, Adalimumab, Methotrexate, BMS-986528, CC-97540
Johnson & JohnsonJNJ2PHASE3Ustekinumab, Guselkumab
AstraZeneca PLCAZN4PHASE2AZD1163, AZD0120, AZD5492, Surovatamig
Novartis AG Sponsored ADRNVS4PHASE2VAY736 PFS, VAY736 AI, PIT565, Secukinumab
Merck & Co., Inc.MRK2PHASE2Tulisokibart, Methotrexate, MK-1045
Sanofi SA Sponsored ADRSNY3PHASE2Sarilumab SAR153191, SAR448501, Leflunomide
AnaptysBio, Inc.ANAB1PHASE2Rosnilimab
Spyre Therapeutics, IncSYRE1PHASE2SPY002-072
Immunovant IncIMVT1PHASE2IMVT-1402
XBiotech, Inc.XBIT1PHASE2Natrunix, Methotrexate
Amgen Inc.AMGN1PHASE2Inebilizumab, Blinatumomab
Artiva Biotherapeutics, Inc.ARTV2PHASE2Allogeneic NK Cells, AB-101, Rituximab, Cyclophosphamide, Fludarabine
Gilead Sciences, Inc.GILD1PHASE1GS-0151
Zenas BioPharma, Inc.ZBIO1PHASE1ZB002
Stryker CorporationSYK5NAUndisclosed
Sonoma Pharmaceuticals, Inc.SNOA2PHASE1SBT777101
Zimmer Biomet Holdings, Inc.ZBH29NAUndisclosed
Adicet Bio IncACET1PHASE1ADI-001, Fludarabine, Cyclophosphamide
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWJun 8, 2026NCT07171983lastUpdatePostDate: changed
LOWJun 8, 2026NCT07171983lastUpdatePostDate: changed
LOWJun 8, 2026NCT07171983lastUpdatePostDate: changed
LOWMay 26, 2026NCT07171983Status: NOT_YET_RECRUITING → RECRUITING
LOWMay 24, 2026NCT07171983studyFirstPostDate: changed